Provided by Tiger Trade Technology Pte. Ltd.

Century Therapeutics, Inc.

1.28
-0.0400-3.03%
Post-market: 1.280.00000.00%16:15 EDT
Volume:697.24K
Turnover:908.59K
Market Cap:231.68M
PE:-1.38
High:1.32
Open:1.29
Low:1.27
Close:1.32
52wk High:3.04
52wk Low:0.4350
Shares:181.00M
Float Shares:101.00M
Volume Ratio:0.63
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9300
EPS(LYR):-0.1107
ROE:-49.65%
ROA:-23.51%
PB:1.00
PE(LYR):-11.56

Loading ...

Century Therapeutics: Cnty-813 Ind Submission Remains on Track for Q4 2026; Initial Clinical Data Anticipated in Second Half of 2027 - SEC Filing

THOMSON REUTERS
·
Oct 02

Century Therapeutics announces presentation of nonclinical data for CNTY-813

TIPRANKS
·
Oct 02

Century Therapeutics Targets CNTY-813 IND Filing in Q4 2026, Sees Initial Trial Data in 2H 2027

Reuters
·
Oct 02

Century Therapeutics Director Joseph Truitt Files Initial Beneficial Ownership Statement

Reuters
·
Sep 11

Century Therapeutics Adds Director, Advances Cell Therapy Pipeline

TIPRANKS
·
Sep 10

Century Therapeutics - Increases Board Size to Seven Directors, Appoints Joseph Truitt Effective Sept 9, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 10

Century Therapeutics Appoints Joseph Truitt to Board of Directors

THOMSON REUTERS
·
Sep 10

Century Therapeutics (IPSC) Gets a Buy from Mizuho Securities

TIPRANKS
·
Aug 18

Phil Nadeau Initiates Buy on Century Therapeutics, Citing Promising T1D Program, Advancing Pipeline, and Strong Cash Runway

TIPRANKS
·
Aug 13

Century Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

MiNK Therapeutics Q2 Loss Narrows on Expense Discipline

Reuters
·
Aug 13

Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations

Reuters
·
Aug 13

Clear Street Sticks to Its Buy Rating for Century Therapeutics (IPSC)

TIPRANKS
·
Aug 13

Century Therapeutics Reports Q2 Results, Pipeline Advancements

TIPRANKS
·
Aug 12

Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss

Reuters
·
Aug 12

Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate

Benzinga Earnings
·
Aug 12

Century Therapeutics Q2 Net Income USD -34.55 Million Vs. IBES Estimate USD -22.4 Million

Reuters
·
Aug 12

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

THOMSON REUTERS
·
Aug 12

Century Therapeutics Q2 Operating Expenses USD 36.527 Million

THOMSON REUTERS
·
Aug 12

Century Therapeutics Q2 Basic EPS USD -0.17

THOMSON REUTERS
·
Aug 12